Poly-ADP ribose polymerase inhibitor have emerged as exciting new chemotherapy options for women with ovarian cancer, especially for patients with BRCA1 or BRCA2 mutations or non-functional homologous recombination repair pathways. Here, BRCA1 is linked to ovarian cancer.